Key Takeaways
- First-quarter net income reached $745 million, an increase from $654 million in the prior-year period
- Quarterly revenue totaled $6.02 billion, below Wall Street’s $6.35 billion projection
- Adjusted earnings per share of $2.60 came in under the consensus forecast of $2.98
- A March cyberattack attributed to Iranian hackers caused operational disruptions affecting quarterly performance
- Shares of SYK declined approximately 2% to $308.75 in extended trading; annual outlook unchanged
The medical technology company delivered a first-quarter performance that exceeded year-over-year profit levels but failed to meet analysts’ revenue and earnings expectations. A cybersecurity incident that occurred in March significantly complicated the quarterly results.
Shares retreated roughly 2% to $308.75 in after-hours market activity after the earnings release.
The medical device manufacturer reported net income of $745 million, equivalent to $1.93 per share, representing growth from the year-ago quarter’s $654 million, or $1.69 per share. Adjusted earnings came to $2.60 per share, falling below the Street’s $2.98 projection.
Quarterly sales reached $6.02 billion for the three months ending March 31. While this represented a 2.6% year-over-year uptick, it underperformed the analyst consensus of $6.35 billion.
Hacking Incident Shadows Performance
A hacking collective known as Handala, reportedly linked to Iran, took credit for launching a destructive cyber assault against Stryker in March. The breach caused significant interruptions to the company’s Microsoft-based infrastructure and allegedly postponed certain surgical operations.
Several employees and contractors shared on social platforms that the hacking group’s emblem appeared during system login attempts, though these reports could not be independently confirmed by Reuters.
The company had previously disclosed in April that the security breach would negatively impact its first-quarter financial performance. Management confirmed this assessment in Thursday’s announcement.
According to Wall Street Journal reporting from the time, the threat actors stated their attack was motivated by retaliatory action against escalating U.S.-Iran tensions.
Division Performance Varies
Stryker’s MedSurg and Neurotechnology division, which represents its largest business unit, generated a 5% sales gain to $3.21 billion. However, this fell short of Wall Street’s $3.83 billion estimate.
The Orthopaedics division delivered comparatively stronger results. Revenue climbed 6.3% to $2.81 billion, surpassing the $2.51 billion analyst projection.
Weaker-than-expected demand for implants and medical devices utilized in sophisticated procedures—including spinal surgery and orthopedic interventions—put pressure on overall performance metrics.
The company faces direct competition from Zimmer Biomet (ZBH) and Johnson & Johnson (JNJ) across the orthopedics landscape, including hip and knee replacement systems, trauma products, and sports medicine equipment.
Notwithstanding the quarter’s underperformance, Stryker maintained its full-year financial outlook. Management reaffirmed expectations for adjusted annual earnings between $14.90 and $15.10 per share.
The decision to keep guidance intact suggests leadership believes the cybersecurity incident’s financial consequences are limited to the first quarter and won’t materially affect full-year projections.
Stryker’s first-quarter adjusted earnings of $2.60 per share, when viewed against the full-year guidance range of $14.90–$15.10 per share, indicates management anticipates accelerated earnings momentum throughout the remaining nine months.
The company confirmed its full-year adjusted earnings per share target of $14.90 to $15.10 remains intact.
